GSE174686
Systematic investigation of cytokine signaling activity at the tissue and single-cell levels
Purpose:  The role of different TGF-beta isoforms in tumor progression is not well established.  The goal of the study was to assess the effect on the 4T1 mouse mammary tumor transcriptomes of treatment with isoform-selective anti-TGFbeta neutralizing antibodies to address whether sparing TGF-beta3 had any biological impact. Methods: 40,000 4T1 cells were implanted in the #4 mammary fatpad of syngeneic female BALB/c mice.  Mice were treated with therapeutic or control antibodies (5mg/Kg i.p. 3x q wk) for 12 days prior to tumor harvest for RNA-Seq analysis. Treatments were:  1D11 pan-TGFbeta mouse monoclonal, XPA.42.681 pan-TGFbeta human monoclonal, XPA.42.089 anti-TGFbeta1+2 human monoclonal, anti-KLH control human monoclonal, 13C4 control mouse monoclonal, or vehicle control.  Tumor mRNA profiles were generated by deep-sequencing of n=5 to 7 samples/treatment group using Illumina HiSeq2500 with TruSeq v4 chemistry. Results:  51-115 million pass-filtered reads were obtained for all samples, with >=91% of bases having a quality score of 30 or above. Overall design: mRNA profiles of 4T1 mouse mammary tumors treated with isoform-selective anti-TGFbeta antibodies were generated by deep sequencing of n=5-7 samples/treatment group by Illumina HiSeq2500